SEC Comment Letter 0000000000-24-009108 to ADC Therapeutics SA (ADCT)
ADC Therapeutics SA
Date: Aug. 9, 2024 · CIK: 0001771910 · Accession: 0000000000-24-009108
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281288
Letter
August 9, 2024 Ameet Mallik Chief Executive Officer ADC Therapeutics SA Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland Re:ADC Therapeutics SA Registration Statement on Form S-3 Filed August 6, 2024 File No. 333-281288 Dear Ameet Mallik: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:David Li
Show Raw Text
August 9, 2024
Ameet Mallik
Chief Executive Officer
ADC Therapeutics SA
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
Re:ADC Therapeutics SA
Registration Statement on Form S-3
Filed August 6, 2024
File No. 333-281288
Dear Ameet Mallik:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:David Li